Irene Braña Archives

The CATHERINE trial begins as the first clinical trial of an innovative CAR-T therapy that triggers a dual anti-tumour response in HER2+ solid tumours

After more than a decade of research, a new-generation CAR-T therapy developed by VHIO, in collaboration with the Hospital del…

Adding immunotherapy before and after surgery improves outcomes in head and neck cancer patients

The phase 3 clinical trial KEYNOTE-689 shows that incorporating the monoclonal antibody pembrolizumab before and after surgery, alongside standard of…

First patient in the world treated with a new therapeutic strategy to target cancer stem cells

A new drug originally developed by Leukos Biotech S.L., a spin-off of the Josep Carreras Leukaemia Research Institute, in collaboration…

Composicióin Dra. Elena Garralda y Dr. Rodrigo Toledo con batas VHIO

VHIO researchers demonstrate the utility of ultrasensitive liquid biopsy to predict and monitor response to immunotherapy

The ultrasensitive liquid biopsy technique applied in this work is based on the sequencing of the entire tumour genome from…

Preliminary results of a first-in-human study show manageable toxicity and preliminary antitumor activity of a potential second generation epigenetic therapy for advanced solid tumor

Published in the journal Clinical Cancer Research (1), preliminary results of a two-part, phase I first-in-human study show encouraging antitumor…

Vall d’Hebron participates in a study that supports the use of pembrolizumab in head and neck squamous cell carcinoma with new data confirming its long-term efficacy

The five-year follow up data from patients in the KEYNOTE-048 trial have been reported, with the participation of Dr. Irene…